[Federal Register Volume 65, Number 156 (Friday, August 11, 2000)]
[Notices]
[Pages 49246-49247]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-20342]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


National Mammography Quality Assurance Advisory Committee; Notice 
of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: National Mammography Quality Assurance Advisory 
Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on September 28, 2000, 9 
a.m. to 6 p.m.
    Location: Holiday Inn, Walker/Whetstone Rooms, Two Montgomery 
Village Ave., Gaithersburg, MD.
    Contact Person: Charles A. Finder, Center for Devices and 
Radiological Health (HFZ-240), Food and Drug Administration, 1350 
Piccard Dr., Rockville, MD 20850, 301-594-3332, or

[[Page 49247]]

FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 
in the Washington, DC area), code 12397. Please call the Information 
Line for up-to-date information on this meeting.
    Agenda: The committee will discuss FDA oversight of the Mammography 
Quality Standards Act (the MQSA) inspectors and inspections, the MQSA 
compliance guidance, and FDA's role under the MQSA in evaluating 
personnel competency. The committee will also receive updates on the 
status of accreditation and certification of full field digital 
mammography, use of small field digital mammography receptors for 
diagnostic examinations, States as certification agencies under the 
MQSA, and the Inspection Demonstration Project. The MQSA compliance 
guidance documents, which are in a question-and-answer format, are 
available to the public on the Internet at http://www.fda.gov/cdrh/mammography. This guidance is being updated continually in response to 
questions that FDA receives from the public. Additional information 
regarding guidance updates may be obtained by calling the Information 
Line.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by September 1, 
2000. Oral presentations from the public will be scheduled between 
approximately 9:30 a.m. and 10:30 a.m. on September 28, 2000. Time 
allotted for each presentation may be limited. Those desiring to make 
formal oral presentations should notify the contact person before 
September 1, 2000, and submit a brief statement of the general nature 
of the evidence or arguments they wish to present, the names and 
addresses of proposed participants, and an indication of the 
approximate time requested to make their presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: August 2, 2000.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 00-20342 Filed 8-10-00; 8:45 am]
BILLING CODE 4160-01-F